Intensity Therapeutics' INT230-6 Prolongs Survival Alone or

/PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary,...

Related Keywords

Westport , Illinois , United States , Chicago , Ottawa , Ontario , Canada , American , Christian Frederick Meyer , Merck Sharpe Dohme , Christianf Meyer , Michael Miller , Bristol Myers Squibb , Lewish Bender , Edna Kaplan , Ottawa Hospital Research Institute , Ontario Institute Of Cancer Research , Drug Administration , Prnewswire Intensity Therapeutics Inc , American Society Of Clinical Oncology , Company On Twitter , Development Agreement , Rx Communications Group , Vaccine Branch , Intensity Therapeutics Inc , Johns Hopkins Sydney Kimmel Cancer Center , National Cancer Institute , Compared To Synthetic Controls , With Favorable , Locally Delivered Cytotoxic Treatment Leading , Systemic Immune Response , Cold Tumors , New Way To Treat , Presented Today , Clinical Oncology , Annual Meeting , First Author , Johns Hopkins Sydney Kimmel Cancer , Session Date , Frederick Meyer , Sidney Kimmel Cancer Center , Johns Hopkins University , Chief Executive Officer , Response Evaluation Criteria , Solid Tumors , Scientific Reports , Royal Marsden Hospital , Kaplan Meier , Merck Sharpe , Ontario Institute , Cancer Research , Cooperative Research , Intensity Therapeutic , Relations Contact , Intensity Therapeutics , Nc ,